| Line 638: | Line 638: | ||
==Smoking Cessation / Preventing Relapse - E-cigarette (ENDS/ANDS)== | ==Smoking Cessation / Preventing Relapse - E-cigarette (ENDS/ANDS)== | ||
===2021: [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub5/full Electronic cigarettes for smoking cessation]=== | |||
*There is moderate‐certainty evidence that ECs with nicotine increase quit rates compared to ECs without nicotine and compared to NRT. | |||
*Citation: Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Butler AR, Fanshawe TR, Hajek P. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2021 Apr 29;4(4):CD010216. doi: 10.1002/14651858.CD010216.pub5. PMID: 33913154; PMCID: PMC8092424. | |||
| Line 683: | Line 688: | ||
*Citation: doi: 10.1016/S2468-2667(20)30307-8 | *Citation: doi: 10.1016/S2468-2667(20)30307-8 | ||
*Acknowledgement: This work was supported by the National Institute on Drug Abuse of the NIH (R01DA037961). his work has also been supported in part by the Biostatistics and Bioinformatics Shared Resource and the Participant Research, Interventions, and Measures Resource at the H Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute designated Comprehensive Cancer Center (P30CA76292). | *Acknowledgement: This work was supported by the National Institute on Drug Abuse of the NIH (R01DA037961). his work has also been supported in part by the Biostatistics and Bioinformatics Shared Resource and the Participant Research, Interventions, and Measures Resource at the H Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute designated Comprehensive Cancer Center (P30CA76292). | ||
======2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186418/ A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes]=== | |||
*An estimated 60%–90% of people with schizophrenia smoke, compared with 15%–24% of the general population, exacerbating the already high morbidity and mortality rates observed in this population. | |||
*Pilot Study - only 40 participants | |||
*Sixteen (40%) participants quit by the end of 12 weeks. For the whole sample, we observed an overall, sustained 50% reduction in smoking or smoking abstinence in 37/40 (92.5%) of participants and an overall 75% reduction in median cigarettes per day from 25 to six was observed by the end of the 12 weeks. | |||
*A high strength nicotine e-cigarette has the potential to help people with schizophrenia spectrum disorders to quit or reduce smoking. Considering that most people with schizophrenia spectrum disorders continue smoking, alternative and efficient interventions to reduce or prevent morbidity and mortality are urgently needed. | |||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186418/pdf/ntab005.pdf PDF Version] | |||
*Citation: Caponnetto P, DiPiazza J, Kim J, Maglia M, Polosa R. A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes. Nicotine Tob Res. 2021;23(7):1113-1122. doi:10.1093/ntr/ntab005 | |||
*Acknowledgement: The authors wish also to thank PAX Labs (on June 13, 2017 the company became known as JUUL Labs) for the free supplies of JUUL e-cigarette kits and pods. At the time the research was conducted JUUL Labs were not part owned by Altria, a tobacco company. PAX Labs agreed also to supply pods for a further 3 months after the end of the pilot to participants who expressed a wish to continue using as JUUL was not available in Italy when this study has been conducted and not currently available at the 5% nicotine strength. | |||
edits